Researchers at The University of Texas MD Anderson Cancer Center have identified a specific protein, RASH3D19, that is ...

Artelo Biosciences, Inc. (Nasdaq: ARTL) (“Artelo” or the “Company”), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with ...

Combined androgen blockade shows significant survival benefits over single-agent ADT in high-risk prostate cancer, as ...

In several disease conditions, including infections and cancers, innate immune activation and nutrient scarcity occur ...

Despite recent progress in understanding the disease, inflammatory breast cancer (IBC) remains a challenge to diagnose and ...

Kura Oncology to Host Virtual Investor Event to Discuss Data Presented at ASH 2025 on Triplet Combination of Ziftomenib (KOMZIFTI®) with Venetoclax and Azacitidine in Newly Diagnosed and ...

A research team led by Park Hyun-woo, a biochemistry professor at Yonsei University, has introduced a pioneering method in ...

After a finite number of divisions, cells simply give up. As each round of replication trims their telomeres-the protective ...

Researchers from the Leibniz Institute on Aging - Fritz Lipmann Institute (FLI) in Jena, Germany, the Molecular Biotechnology ...

Cancer remains one of the most critical global public health challenges, exerting profound social, economic, and clinical ...

Kura Oncology, Inc. (NASDAQ: KURA) shares were considerably lower in the first hour or Tuesday. The San Diego-based a biopharmaceutical company committed to realizing the promise of precision ...

Elevar plans resubmission of a New Drug Application to the U.S. Food and Drug Administration for the combination therapy of camrelizumab and rivoceranib in January 2026.